
EAST - [default.wsp:1]
File View Edit Tools Window Help
L2: (75814
L3: (0) 1
L4: (15131
L5: (10660
L6: (65409
L7: (36233
L8: (59) 5
L9: (5) 8
L10: (256)
L11: (1744
L12: (81)
L13: (12)
Failed
Detailed Description Text - DETX (10):
6. Chemotherapeutic substance--Refers to a therapeutically active substance whose therapeutic effect arises from the chemical characteristics of the substance. Chemotherapeutic substances may include, for example, non-radioactive pharmaceuticals. They may include small molecules or more complex molecules such as lipids, carbohydrates, proteins or nucleic acids such as DNA or RNA.
Detailed Description Text - DETX (19):
Proteinaceous substances, including proteins, glycoproteins, lipoproteins or
BRS form
IS&R form
Image
Text
HTML
U
1
Document ID
Issue Date
Pages
Title
Current
Curren
Re
Invento
5 US 5872107 A 19990216 36 Treatment of urogenital cancer with boron 514/44 424/1.73; Schinazi, Raym et al.
6 US 5851510 A 19981222 32 Hepatocyte-selective oil-in-water emulsion 424/9.45 424/1.89; Counsell, Raym et al.
7 US 5725838 A 19980310 5 Radiolabeled D4 receptor ligands 424/1.85 424/1.81; Pollak, Alfred
8 US 5690906 A 19971125 22 Dopamine D-3 and serotonin (5-HT.sub.1A) 424/1.85 544/101; Kung, Hank F.
9 US 5667764 A 19970916 46 Compounds, compositions and methods for binding 424/1.45 424/1.53; Kopia, Gregory al.
10 US 5599796 A 19970204 35 Treatment of urogenital cancer with boron 514/44 424/1.11; Schinazi, Raym et al.
Hits
Details
HTML
Ready
NUM


EAST - [default.wsp:1]
File View Edit Tools Window Help
L15: (5) 1
L16: (0) 1
L17: (2) 1
L18: (5814
L19: (13)
L20: (1) 1
L21: (154)
L22: (2830
L23: (1823
L24: (30)
L25: (25)
Failed
Saved
Detailed Description Text - DETX (21):
The "targeting moiety" of the present invention binds to a defined target cell population, such as tumor cells. Preferred targeting moieties useful in this regard include antibody and antibody fragments, peptides, and hormones. Proteins corresponding to known cell surface receptors (including low density lipoproteins, transferrin and insulin), melanocyte stimulating hormone, somatostatin, somatostatin derivatives, such as octreotide and MK-678 (Merck), fibrinolytic enzymes, HER2 ligand, and biological response modifiers (including interleukin, interferon, erythropoietin and colony-stimulating factor) are also preferred targeting moieties. Oligonucleotides, e.g., antisense oligonucleotides that are complementary to portions of target cellular nucleic acids (DNA or RNA), are also useful as targeting moieties in the practice of the present invention. Oligonucleotides binding to cell surfaces are also
BRS form
ISR form
Image
Text
HTML
U
1
Document ID
Issue Date
Pages
Title
Current
Curren
Re
Invento
15 US 5679318 A 19971021 Stable therapeutic radionuclide 424/1.11 424/1.45; Vanderheyden, et al.
16 US 5630996 A 19970520 Two-step pretargeting methods using improved 424/1.49 424/1.53; Reno, John M.
17 US 5607659 A 19970304 36 Directed biodistribution of radiolabelled biotin 424/1.73 514/387 Gustavson, Li al.
18 US 5541287 A 19960730 68 Pretargeting methods and compounds 530/317 530/323; Yau, Eric K. e
19 US 5492839 A 19960220 20 Immunogenic ryanodine derivative and related 436/504 436/545; Campbell, Kevi al.
20 US 5393512 A 19950228 10 Stable therapeutic radionuclide 424/1.53 424/1.11; Vanderheyden,
Hits
Details
HTML
Ready
NUM

EAST - [default.wsp:1]

File View Edit Tools Window Help

- L15: (5) 1
- L16: (0) 1
- L17: (2) 1
- L18: (5814
- L19: (13)
- L20: (1) 1
- L21: (154)
- L22: (2830
- L23: (1823
- L24: (30)
- L25: (25)
- Failed
- Saved

incorporated into these conjugates of the present invention.

Detailed Description Text - DETX (109):

Briefly, iodobenzamide derivatives corresponding to biocytin (R=COOH) and biotinamidopentylamine (R=H) were prepared according to the following scheme. In this scheme, "X" may be any radiohalogen, including .sup.125 I, .sup.131 I, .sup.123 I, .sup.211 At and the like. ##STR26## Preparation of 1 was generally according to Wilbur et al., J. Nucl. Med. 30:216-26, 1989, using a tributyltin intermediate. Water soluble carbodiimide was used in the above-depicted reaction, since the NHS ester 1 formed intractable mixtures with DCU. The NHS ester was not compatible with chromatography; it was insoluble in organic and aqueous solvents and did not react with biocytin in DMF or in buffered aqueous acetonitrile. The reaction between 1 and biocytin

BRS form | ISR form | Image | Text | HTML

| | U | 1 | Document ID | Issue Date | Pages | Title | Current | Curren | Re | Inventc |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 | ☑ | ☐ | US 5679318 A | 19971021 | | Stable therapeutic radionuclide | 424/1.11 | 424/1.45; | | Vanderheyden, et al. |
| 16 | ☑ | ☐ | US 5630996 A | 19970520 | | Two-step pretargeting methods using improved | 424/1.49 | 424/1.53; | | Reno, John M. |
| 17 | ☐ | ☐ | US 5607659 A | 19970304 | 36 | Directed biodistribution of radiolabelled biotin | 424/1.73 | 514/387 | | Gustavson, Li al. |
| 18 | ☐ | ☐ | US 5541287 A | 19960730 | 68 | Pretargeting methods and compounds | 530/317 | 530/323; | | Yau, Eric K. e |
| 19 | ☐ | ☐ | US 5492839 A | 19960220 | 20 | Immunogenic ryanodine derivative and related | 436/504 | 436/545; | | Campbell, Kevi al. |
| 20 | ☐ | ☐ | US 5393512 A | 19950228 | 10 | Stable therapeutic radionuclide | 424/1.53 | 424/1.11; | | Vanderheyden, et al. |

Hits | Details | HTML

Ready NUM




| | Type | L # | Hits | Search Text | DBs | Time Stamp | Comments | Error Definition | Err |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IS&R | L1 | 1 | ("6461585").PN. | USPAT | 2003/11/03 09:58 | | | 0 |
| 2 | BRS | L2 | 151312 | peptide$1 or protein$1 | USPAT | 2003/11/03 09:58 | | | 0 |
| 3 | BRS | L3 | 0 | 1 and 2 | USPAT | 2003/11/03 09:58 | | | 0 |
| 4 | BRS | L4 | 65281 | antibod$3 | USPAT | 2003/11/03 09:58 | | | 0 |
| 5 | BRS | L5 | 0 | 1 and 4 | USPAT | 2003/11/03 09:58 | | | 0 |
| 6 | BRS | L6 | 14018 | benzamid$ | USPAT | 2003/11/03 09:58 | | | 0 |
| 7 | BRS | L7 | 0 | 1 and 2 | USPAT | 2003/11/03 09:59 | | | 0 |
| 8 | BRS | L8 | 17803 | divinylbenzene | USPAT | 2003/11/03 09:59 | | | 0 |
| 9 | BRS | L9 | 1 | 1 and 8 | USPAT | 2003/11/03 09:59 | | | 0 |
| 10 | BRS | L10 | 236 | 424/1.81-1.85.ccls. | USPAT | 2003/11/03 10:00 | | | 0 |
| 11 | BRS | L11 | 155604 | sn or tin or alkyltin or | USPAT | 2003/11/03 | | | 0 |




| | Type | L # | Hits | Search Text | DBs | Time Stamp | Comments | Error Definition | Err |
|---|---|---|---|---|---|---|---|---|---|
| 9 | BRS | L9 | 1 | 1 and 8 | USPAT | 2003/11/03 09:59 | | | 0 |
| 10 | BRS | L10 | 236 | 424/1.81-1.85.ccls. | USPAT | 2003/11/03 10:00 | | | 0 |
| 11 | BRS | L11 | 155604 | sn or tin or alkyltin or trialkyl-sn | USPAT | 2003/11/03 10:00 | | | 0 |
| 12 | BRS | L12 | 70 | 10 and 11 | USPAT | 2003/11/03 10:00 | | | 0 |
| 13 | BRS | L14 | 1093382 | support$1 | USPAT | 2003/11/03 10:00 | | | 0 |
| 14 | BRS | L15 | 17 | 13 and 14 | USPAT | 2003/11/03 10:01 | | | 0 |
| 15 | BRS | L13 | 42 | 12 and 2 | USPAT | 2003/11/03 10:05 | | | 0 |
| 16 | BRS | L16 | 38 | ((sn or tin) and (peptide$ or protein$1)).ab,ti. | USPAT | 2003/11/03 10:06 | | | 0 |
| 17 | BRS | L17 | 36233 | radio$.ab,ti. | USPAT | 2003/11/03 10:06 | | | 0 |
| 18 | BRS | L18 | 11 | 16 and 17 | USPAT | 2003/11/03 10:06 | | | 0 |




| | Type | L # | Hits | Search Text | DBs | Time Stamp | Comments | Error Definition | Err |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IS&R | L1 | 2 | (("5213787") or ("5302700")).PN. | USPAT | 2003/11/03 16:01 | | | 0 |
| 2 | BRS | L2 | 75814 | dna or nucleoside$1 or nucleotide$1 or nucleic | USPAT | 2003/11/03 16:02 | | | 0 |
| 3 | BRS | L3 | 0 | 1 and 2 | USPAT | 2003/11/03 16:02 | | | 0 |
| 4 | BRS | L4 | 151312 | peptide$1 or protein$1 | USPAT | 2003/11/03 16:02 | | | 0 |
| 5 | BRS | L5 | 10660 | (sn or tributyl or tributyltin or trialkyl or | USPAT | 2003/11/03 16:18 | | | 0 |
| 6 | BRS | L6 | 65409 | 2 and 4 | USPAT | 2003/11/03 16:03 | | | 0 |
| 7 | BRS | L7 | 36233 | radio$.ab,ti. | USPAT | 2003/11/03 16:03 | | | 0 |
| 8 | BRS | L8 | 59 | 5 and 6 | USPAT | 2003/11/03 16:04 | | | 0 |
| 9 | BRS | L9 | 5 | 8 and 7 | USPAT | 2003/11/03 16:06 | | | 0 |
| 10 | BRS | L10 | 256 | 424/1.81-1.89.ccls. | USPAT | 2003/11/03 16:06 | | | 0 |
| 11 | BRS | L11 | 174492 | sn or tributyl or tributyltin or trialkyl or | USPAT | 2003/11/03 16:06 | | | 0 |
| 12 | BRS | L12 | 81 | 10 and 11 | USPAT | 2003/11/03 16:07 | | | 0 |
| 13 | BRS | L13 | 12 | 12 and 6 | USPAT | 2003/11/03 16:17 | | | 0 |
| 14 | BRS | L14 | 97 | 5 and 2 | USPAT | 2003/11/03 | | | 0 |

EAST - [default.wsp: 1]

File View Edit Tools Window Help

BRS form | IS&R form | Image | Text | HTML

| | Type | L # | Hits | Search Text | DBs | Time Stamp | Comments | Error Definition | Err |
|---|---|---|---|---|---|---|---|---|---|
| 13 | BRS | L13 | 12 | 12 and 6 | USPAT | 2003/11/03 16:17 | | | 0 |
| 14 | BRS | L14 | 97 | 5 and 2 | USPAT | 2003/11/03 16:14 | | | 0 |
| 15 | BRS | L15 | 5 | 14 and 7 | USPAT | 2003/11/03 16:14 | | | 0 |
| 16 | BRS | L16 | 0 | 15 not 9 | USPAT | 2003/11/03 16:14 | | | 0 |
| 17 | BRS | L17 | 2 | 14 and 10 | USPAT | 2003/11/03 16:15 | | | 0 |
| 18 | BRS | L18 | 5814 | 11 and 2 | USPAT | 2003/11/03 16:15 | | | 0 |
| 19 | BRS | L19 | 13 | 18 and 10 | USPAT | 2003/11/03 16:15 | | | 0 |
| 20 | BRS | L20 | 1 | 19 not 13 | USPAT | 2003/11/03 16:15 | | | 0 |
| 21 | BRS | L21 | 154 | 18 and 7 | USPAT | 2003/11/03 16:17 | | | 0 |
| 22 | BRS | L22 | 28300 | tributyl or tributyltin or trialkyl or trialkyltin o | USPAT | 2003/11/03 16:19 | | | 0 |
| 23 | BRS | L23 | 1823 | 22 and 2 | USPAT | 2003/11/03 16:19 | | | 0 |
| 24 | BRS | L24 | 30 | 23 and 7 | USPAT | 2003/11/03 16:19 | | | 0 |
| 25 | BRS | L25 | 25 | 24 and 4 | USPAT | 2003/11/03 16:19 | | | 0 |

Hits | Details | HTML

Ready NUM